eftilagimod alpha,pembrolizumab
Immutep,Merck
['ease,(-please),(-disease),(-incrrease),(-decrease)', 'tacti-002', 'immutep', '$immp']
 's tacti-002 results in 1st line nsclc patients reported today at #sitc22 include an overall response rate to increased 40.4% &amp; interim median duration of response of 21.6 months, comparing favourably to historical controls.
more: #lag3 $imm $immp 